This led to the initiation of a clinical trial to evaluate the effectiveness of AML DC hybrid vaccines, in combination with a blockade of the PDL-1/PD-1 pathway in a multicenter study performed in 63 AML subjects enrolled in April 2024 (NCT01096602). Here, CD274 is linked to acute myeloid leukemia.